Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid Tumors

Completed · Phase 1

Conditions studied: Solid Tumor

In brief

This is an open-label Phase I study to evaluate the safety, tolerability, and pharmacokinetics of escalating oral doses of GDC-0919, an investigational agent intended to inhibit the indoleamine 2,3-dioxygenase 1 (IDO1) enzyme and help the human immune system attack solid tumor cells more effectively.

Key facts

Study ID

NCT02048709

Run by

Genentech, Inc.

People needed

22

Starts

2014-04-01

Expected to finish

2016-02-01

Last updated by the study team

2017-02-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically or cytologically confirmed solid tumor that is relapsed/refractory to standard therapies or for which no approved or curative therapy exists
• Age > or = 18
• Eastern Cooperative Oncology Group (ECOG) performance status < 2
• Life expectancy > or = 12 weeks
• Adequate hematologic and organ function before initiation of GDC-0919
• For some patients only: Accessible lesions amenable to paired fresh tumor biopsies

You may not qualify if…

• Some prior cancer immunotherapies
• Untreated brain metastases
• Active or history of autoimmune disease

Where it is running

• Georgia Regents University — Augusta, Georgia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.